Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. (RGLS), sold 10,300 shares at $6.64 ($69K) on 2014-10-02, disclosed to the SEC on 2014-10-03.
Scheduled sale ($69k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.71 | 3,250 | $22K | 31.4% |
| 2 | $6.64 | 3,750 | $25K | 35.9% |
| 3 | $6.88 | 3,300 | $23K | 32.7% |
| Total | $6.74 avg | 10,300 | $69K | 100% |
| Filing → |
| RGLS | SELL | 2014-10-24 | $1.6M | — | Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |